Delamanid (as part of a longer oral regimen)
Treatment for HIV/AIDS - Multidrug-resistant Tuberculosis without extensive drug resistance
Typical Dosage: 100mg twice daily for 24 weeks
Effectiveness
75%
Safety Score
65%
Clinical Trials
25
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
100mg twice daily for 24 weeks
Time to Effect
2-3 months for significant clinical improvement
Treatment Duration
Delamanid component 6-9 months, total regimen 9-18 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
82%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$4,000
Side Effect Mgmt:$2,500
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
9
Outcome-Based Costs
Cost per Responder
$62,000
Cost per Remission
$62,000
Comparison vs Older, longer MDR-TB regimens without Delamanid
Cost Difference
+$3,000/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Delamanid (as part of a longer oral regimen) Outcomes
for HIV/AIDS - Multidrug-resistant Tuberculosis without extensive drug resistance
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+75%
Common Side Effects
QT prolongation
+10%
Headache
+20%
Nausea
+12%
Peripheral neuropathy
+7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov